According to the research report titled ‘Global Transcatheter Tricuspid Valve Intervention (TTVI) Market - Analysis By Intervention Type (TVr, TVR), Disease Type (TR, TS), End User, By Region, By Country (2021 Edition): Market Insights, Pipeline, COVID-19 Implications, Competition and Forecast (2021-2030)’, available with MarketStudyReport, global transcatheter tricuspid valve intervention (TTVI) market is expected to account for USD 10.17 billion in valuation by 2030.

The rising geriatric population, increasing prevalence of tricuspid valve diseases, mounting preference for TTVI devices for treatment, technological advancements, and growing demand for minimally invasive surgeries are some of the factors projected to fuel the growth of global transcatheter tricuspid valve intervention market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4331005/  

Positive approval ratings across the globe are also aiding towards the market expansion. However, the COVID-19 outbreak has severely affected industries including cardiovascular care. It has also disrupted the clinical & confirmatory trials, regulatory clearances, pipeline milestones, and approvals of tricuspid valve replacement & repair devices, thus negatively impacting the global transcatheter tricuspid valve intervention industry outlook.

Based on intervention type, the market is divided into Tricuspid Valve Replacement (TVR) and Tricuspid Valve Repair (TVR). Moving on to disease type, the market is fragmented in terms of Tricuspid Stenosis (TS) and Tricuspid Regurgitation (TR).

Citing the end-user spectrum, the market is segmented into hospitals, ambulatory surgical centers, and others.

The geographical analysis of this business sphere extends to Latin America, Europe, North America, Middle East & Africa, and Asia Pacific with major emphasis on countries such as China, Australia, France, Germany, Canada, India, Japan, Italy, the U.K., and the U.S.

The report claims that Europe is estimated to be the fastest-growing market over the period of 2021-2025, owing to favorable approval ratings for tricuspid valve repair devices, rising prevalence of tricuspid valve disorders, high per-capita healthcare expenditure, and mounting aging population.

Meanwhile, Asia-Pacific is expected to take the lead in terms of market share during the second half from 2026-2030, primarily attributed to the rapidly expanding healthcare infrastructure, increasing prevalence of tricuspid valve disorders, the surge in medical tourism, and rising healthcare expenditure.

HuiHe Healthcare Company, NaviGate Cardiac Structures Inc., 4Tech Cardio Ireland Ltd., Jenscare Scientific Co. Ltd., Venus MedTech HangZhou Inc., CryoLife Inc., LivaNova plc, Medtronic plc, Abbott Laboratories, and Edwards Lifesciences are the major players operating in the global transcatheter tricuspid valve intervention market.